Plasminogen–streptokinase activator complex (SK-PLG)

The Plasminogen–streptokinase activator complex is a high-affinity molecular assembly formed when the bacterial protein streptokinase binds to human plasminogen in a 1:1 stoichiometric ratio (StatPearls, NBK553211). This complex is unique because streptokinase itself lacks intrinsic enzymatic activity; instead, it functions by inducing a conformational change in the plasminogen molecule that exposes its active site without requiring proteolytic cleavage (PubChem, CID 16129708). Once formed, this activator complex functions as a potent serine protease that catalytically converts free, circulating plasminogen into active plasmin, the primary enzyme responsible for the dissolution of fibrin-rich blood clots (DrugBank, DB00086). Clinically, this mechanism is exploited through the administration of streptokinase to treat life-threatening conditions such as acute myocardial infarction, pulmonary embolism, and deep vein thrombosis (NIH, PubMed). Because the complex does not require fibrin for its activation, it promotes systemic fibrinolysis, which can lead to a depletion of circulating fibrinogen and an increased risk of major hemorrhage (Wikipedia, Streptokinase). Additionally, the bacterial origin of streptokinase makes the complex highly antigenic, potentially leading to allergic reactions or reduced therapeutic efficacy in patients with high titers of pre-existing anti-streptococcal antibodies (StatPearls, NBK553211).

Other names

Streptokinase-plasminogen complexSK-plasmin complexAnisoylated plasminogen streptokinase activator complexAPSACStreptokinase-plasmin activator complex

Streptokinase binds to plasminogen in a 1:1 stoichiometric ratio to form an activator complex. This binding induces a conformational change in the plasminogen molecule, exposing an active site that can then catalytically convert additional, free plasminogen molecules into the active enzyme plasmin, which subsequently degrades fibrin clots.